These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38534728)

  • 1. B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia.
    Ntsethe A; Mkhwanazi ZA; Dludla PV; Nkambule BB
    Curr Issues Mol Biol; 2024 Feb; 46(3):1731-1740. PubMed ID: 38534728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
    Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
    Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?
    Mertowska P; Mertowski S; Smolak K; Kita G; Guz K; Kita A; Pasiarski M; Smok-Kalwat J; Góźdź S; Grywalska E
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
    Arruga F; Gyau BB; Iannello A; Vitale N; Vaisitti T; Deaglio S
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population.
    Suwalska K; Pawlak E; Karabon L; Tomkiewicz A; Dobosz T; Urbaniak-Kujda D; Kuliczkowski K; Wolowiec D; Jedynak A; Frydecka I
    Hum Immunol; 2008 Mar; 69(3):193-201. PubMed ID: 18396212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
    Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
    Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.
    Vodárek P; Écsiová D; Řezáčová V; Souček O; Šimkovič M; Vokurková D; Belada D; Žák P; Smolej L
    Cancer Med; 2023 Mar; 12(6):6956-6970. PubMed ID: 36440594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.
    Kolacinska A; Cebula-Obrzut B; Pakula L; Chalubinska-Fendler J; Morawiec-Sztandera A; Pawlowska Z; Zawlik I; Morawiec Z; Jesionek-Kupnicka D; Smolewski P
    Oncol Lett; 2015 Aug; 10(2):1079-1086. PubMed ID: 26622629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD163 impact as a prognostic biomarker in chronic lymphocytic leukemia.
    Ragab HM; Attia HRM; Maksoud NA; Ibrahim MH; Mohamed MM; Kamel A; Sobeih ME; Kamal MAM; Abd Elaziz W
    Egypt J Immunol; 2023 Jul; 30(3):74-81. PubMed ID: 37440184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.